Guides for diagnostic development
The pathway follows your test's risk and whether a similar test is already on the market. Most moderate-risk tests with a predicate go through a 510(k). A new moderate-risk test with no predicate goes through De Novo. High-risk tests, including most companion diagnostics, need premarket approval (PMA).
At a glance
Class II (some Class I)
When it fits
A legally marketed predicate exists
What you must show
Substantial equivalence to the predicate
Typical evidence
Analytical validation and method comparison; clinical data sometimes
FDA review goal (MDUFA V)
90 FDA days for 95% of submissions
Class I or II, new type
When it fits
No predicate; low to moderate risk manageable by special controls
What you must show
Reasonable assurance of safety and effectiveness, plus proposed special controls
Typical evidence
Analytical validation and usually clinical performance data
FDA review goal (MDUFA V)
150 FDA days for 70% of requests
Class III
When it fits
High risk, such as most companion diagnostics
What you must show
Reasonable assurance of safety and effectiveness
Typical evidence
Full analytical and clinical studies, manufacturing review, often an inspection
FDA review goal (MDUFA V)
About 285–290 days total time to decision
"FDA days" exclude time the clock is stopped while you answer FDA's questions, so calendar time is longer. MDUFA VI goals start October 2027.
One real example
Every pathway
We design and run the validation studies, write the submission and run cleared tests in our CLIA/CAP laboratory.